# Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety

> **NCT00621270** · PHASE2 · COMPLETED · sponsor: **BrainCells Inc.** · enrollment: 115 (actual)

## Conditions studied

- Major Depressive Disorder
- Anxiety

## Interventions

- **DRUG:** BCI-540

## Key facts

- **NCT ID:** NCT00621270
- **Lead sponsor:** BrainCells Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2011-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621270, "Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00621270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*